Antibodies specifically binding pd-1, tim-3 or pd-1 and tim-3 and their uses
AssigneeJanssen Biotech, Inc.
InventorsRaluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Claims96
1) (canceled)
2) (canceled)
3) (canceled)
4) (canceled)
5) (canceled)
6) (canceled)
7) (canceled)
8) (canceled)
9) (canceled)
10) (canceled)
11) A polynucleotide
- a) encoding the VH of SEQ ID NOs:
- 41, 42, 43 or 48;
- b) encoding the VL of SEQ ID NOs:
- 49, 50, 51, 52, 53, 54, 55 or 56;
- c) encoding the VH of SEQ ID NOs:
- 41, 42, 43 or 48 and the VL of SEQ ID NOs:
- 49, 50, 51, 52, 53, 54, 55 or 56;
- or
- d) comprising the polynucleotide sequence of SEQ ID NOs:
- 196 or 197.
15) (canceled)
16) (canceled)
17) A polynucleotide
- a) encoding the VH of SEQ ID NO:
- 64;
- b) encoding the VL of SEQ ID NO:
- 65;
- c) encoding the VH of SEQ ID NO:
- 64 and the VL of SEQ ID NO:
- 65;
- or
- d) comprising the polynucleotide sequence of SEQ ID NOs:
- 198 or 199.
21) A method of treating a cancer in a subject, comprising administering a therapeutically effective amount of an isolated antibody or the antigen-binding portion thereof to the subject in need thereof for a time sufficient to treat the cancer wherein the isolated antibody or the antigen-binding portion thereof comprises an HCDR1, HCDR2, and HCDR3, and an LCDR1, LCDR2, and LCDR3 of SEQ ID NOs:
- (a) 10, 13, 16, 20, 26 and 31, respectively;
- (b) 10, 13, 16, 21, 26 and 32, respectively;
- (c) 10, 14, 16, 22, 27 and 33, respectively;
- (d) 10, 14, 16, 22, 26 and 34, respectively;
- (e) 10, 14, 16, 23, 28 and 35, respectively;
- (f) 10, 13, 17, 20, 26 and 31, respectively;
- (g) 10, 13, 17, 20, 26 and 36, respectively;
- (h) 10, 13, 17, 21, 26 and 32, respectively;
- (i) 10, 13, 17, 21, 27 and 37, respectively;
- (j) 10, 13, 17, 23, 26 and 32, respectively;
- (k) 10, 14, 17, 23, 28 and 35, respectively;
- (l) 10, 14, 17, 22, 26 and 34, respectively;
- or
- (m) 10, 14, 17, 23, 26 and 32, respectively.
22) A method of treating a cancer in a subject, comprising administering a therapeutically effective amount of the isolated antibody or the antigen-binding portion thereof to the subject in need thereof for a time sufficient to treat the cancer wherein the isolated antibody or the antigen-binding fragment thereof comprises
- (a) an HCDR1, HCDR2, and HCDR3, and an LCDR1, LCDR2, and LCDR3 of SEQ ID NOs:
- 66, 67, 68, 69, 70 and 71, respectively;
- (b) a VH of SEQ ID NO:
- 64 and a VL of SEQ ID NO:
- 65;
- and/or
- (c) a HC of SEQ ID NO:
- 74 and a LC of SEQ ID NO:
- 75.
26) A method of enhancing an immune response in a subject, comprising administering a therapeutically effective amount of an antibody or the antigen-binding portion thereof to the subject in need thereof for a time sufficient to enhance the immune response wherein the antibody or the antigen-binding portion thereof comprises an HCDR1, HCDR2, and HCDR3, and an LCDR1, LCDR2, and LCDR3 of SEQ ID NOs:
- (a) 10, 13, 16, 20, 26 and 31, respectively;
- (b) 10, 13, 16, 21, 26 and 32, respectively;
- (c) 10, 14, 16, 22, 27 and 33, respectively;
- (d) 10, 14, 16, 22, 26 and 34, respectively;
- (e) 10, 14, 16, 23, 28 and 35, respectively;
- (f) 10, 13, 17, 20, 26 and 31, respectively;
- (g) 10, 13, 17, 20, 26 and 36, respectively;
- (h) 10, 13, 17, 21, 26 and 32, respectively;
- (i) 10, 13, 17, 21, 27 and 37, respectively;
- (j) 10, 13, 17, 23, 26 and 32, respectively;
- (k) 10, 14, 17, 23, 28 and 35, respectively;
- (l) 10, 14, 17, 22, 26 and 34, respectively;
- or
- (m) 10, 14, 17, 23, 26 and 32, respectively.
31) An anti-idiotypic antibody binding to an antibody or the antigen-binding portion thereof wherein the antibody or the antigen-binding portion thereof comprises an HCDR1, HCDR2, and HCDR3, and an LCDR1, LCDR2, and LCDR3 of SEQ ID NOs:
- (a) 10, 13, 16, 20, 26 and 31, respectively;
- (b) 10, 13, 16, 21, 26 and 32, respectively;
- (c) 10, 14, 16, 22, 27 and 33, respectively;
- (d) 10, 14, 16, 22, 26 and 34, respectively;
- (e) 10, 14, 16, 23, 28 and 35, respectively;
- (f) 10, 13, 17, 20, 26 and 31, respectively;
- (g) 10, 13, 17, 20, 26 and 36, respectively;
- (h) 10, 13, 17, 21, 26 and 32, respectively;
- (i) 10, 13, 17, 21, 27 and 37, respectively;
- (j) 10, 13, 17, 23, 26 and 32, respectively;
- (k) 10, 14, 17, 23, 28 and 35, respectively;
- (l) 10, 14, 17, 22, 26 and 34, respectively;
- or
- (m) 10, 14, 17, 23, 26 and 32, respectively.
32) (canceled)
33) (canceled)
34) (canceled)
35) (canceled)
36) (canceled)
37) (canceled)
38) (canceled)
39) (canceled)
40) (canceled)
41) (canceled)
42) (canceled)
43) (canceled)
44) (canceled)
45) (canceled)
46) (canceled)
47) (canceled)
48) (canceled)
49) (canceled)
50) (canceled)
51) (canceled)
52) (canceled)
53) (canceled)
54) (canceled)
55) (canceled)
56) (canceled)
57) (canceled)
58) (canceled)
59) (canceled)
60) (canceled)
61) (canceled)
62) (canceled)
63) (canceled)
64) (canceled)
65) (canceled)
66) (canceled)
67) (canceled)
68) (canceled)
69) (canceled)
70) (canceled)
71) (canceled)
72) (canceled)
73) (canceled)
74) (canceled)
75) (canceled)
76) (canceled)
77) (canceled)
78) (canceled)
79) (canceled)
80) (canceled)
81) (canceled)
82) (canceled)
83) (canceled)
84) (canceled)
85) (canceled)
86) (canceled)
87) (canceled)
88) (canceled)
89) (canceled)
Dependencies are inferred from the claim text.